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 ABSTRACT 
 
Objective: To identify risk factors for pain and functional deterioration in people with knee and hip 
osteoarthritis (OA) to form the basis of a future ‘stratification tool’ for OA development or 
progression. 
 
Design: Systematic review and meta-analysis 
 
Methods: An electronic search of the literature databases: MEDLINE, EMBASE, CINAHL, MEDLINE 
and Web of Science (1990-February 2020) was conducted. Studies which identified risk factors for 
pain and functional deterioration to knee and hip OA were included. Where data and study 
heterogeneity permitted, meta-analyses presenting mean difference (MD) and odd ratios (OR) with 
corresponding 95% confidence intervals (CI) were undertaken. Where this was not possible, a 
narrative analysis was undertaken. The Downs & Black tool assessed methodological quality of 
selected studies before data extraction. Pooled analysis outcomes were assessed and reported using 
the GRADE approach. 
 
Results:  82 studies (41,810 participants) were included. On meta-analysis: there was moderate 
quality evidence that knee OA pain was associated with factors including: Kellgren and Lawrence≥ 2 
(MD: 2.04, 95% CI:1.48,2.81; p<0.01), increasing age (MD: 1.46, 95% CI:0.26,2.66; p=0.02) and 
whole-organ MRI scoring method Knee effusion score ≥1 (OR: 1.35, 95% CI: 0.99,1.83; p=0.05). On 
narrative analysis: knee OA pain was associated with factors including WORMS meniscal damage≥1 
(OR: 1.83). Predictors of joint pain in hip OA were large acetabular bone marrow lesions (OR: 5.23), 
chronic widespread pain (OR: 5.02) and large hip BMLs (OR: 4.43).  
 
Conclusions: Our study identified risk factors for clinical pain in OA by imaging measures that can 
assist in predicting and stratifying people with knee/hip OA. A ‘stratification tool’ combining verified 
risk factors that we have identified, would allow selective stratification based on pain and structural 
outcomes in OA.  
 
PROSPERO Registration: CRD42018117643 
 
ARTICLE SUMMARY: strengths and limitations of this study 
 
• This study has been reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses reporting checklist.  
• Analyses have been undertaken respecting potential sources of know statistical 
heterogeneity. 
• Searches included both published and unpublished sources of literature to reduce the risk of 
omitting potentially eligible data. 
• There was a paucity of available data to permit meta-analyses of risk factors for pain and 
functional impairment. 
• The variability in methods of assessing risk and reporting of frequency of risk characteristics 
limited analyses 
  
INTRODUCTION 
 
It has been reported that over 30.8 million US adults suffer from osteoarthritis (OA) (1). Between 
1990-2010, the years lived with disability worldwide caused by OA increased from 10.5 million to 
17.1 million, an increase of 62.9% (2). Current OA treatment lacks any disease-modifying treatments 
with a predominance to manage symptoms rather than modify underlying disease (3). The clinical 
symptoms of OA can be assessed using several questionnaires, the most common of which is the 
Western Ontario McMaster Arthritic Index (WOMAC) (4,5,6). Although pain is recognised as an 
important outcome measure in OA, it is not clear what the optimal assessment tools are in OA and 
how they relate to other risk factors.  
 
OA has various subtypes and since current therapies cannot prevent OA progression, early detection 
and stratification of those at risk may enable effective pre-symptomatic interventions (7,8). Several 
methods are used to define, diagnose and measure OA progression, including imaging techniques 
[e.g. plain radiography, Computed Tomography (CT) and Magnetic Resonance Imaging (MRI)]. Plain 
radiography provides high contrast and high resolution images for cortical and trabecular bone, but 
not for non-ossified structures (e.g. synovial fluid) (9). The most recognised radiographic measure 
classifying OA severity is Kellgren and Lawrence (KL) grading which assesses osteophytes, joint space 
narrowing (JSN), sclerosis and bone deformity (10,11). However, it has been argued that MRI may be 
more suitable for imaging arthritic joints, providing a whole organ image of the joint (12). Whole-
organ MRI scoring method (WORMS) is used in MRI for OA assessing damage, providing a detailed 
analysis of the joint.  
 
Recently, OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society 
International) have published a core domain set for clinical trials in hip and/or knee OA (13). Six 
domains were assessed as mandatory in the assessment of OA, including pain, physical function, 
quality of life, patient’s global assessment of the target joint, and adverse events including mortality 
and/or joint structure, depending on the intervention tested. However, there remains a need to 
identify risk factors for pain and structural damage in OA so that potential interventions can be 
studied in a timely manner. The purpose of this systematic review was therefore to identify risk 
factors for pain, worsening function and structural damage that can predict knee/hip OA 
development and progression. By identifying risk factors for OA pain and structural damage, tools 
for stratifying specific disease groups could be developed in the future. 
 
METHODS 
 
This systematic review has been reported in accordance with the PRISMA reporting guidelines. The 
review protocol was registered a priori through PROSPERO (Registration: CRD42018117643). 
 
Search Strategy 
A systematic search of the literature was undertaken from 1st January 1990 to 1st February 2020 
using electronic databases: MEDLINE (Ovid), EMBASE (Ovid), MEDLINE, Web of Science and CINAHL 
(EBSCO). An example of the EMBASE search strategy of included search terms and Boolean 
operators is presented in Supplementary File 1. Unpublished literature databases including 
Clinicaltrials.gov, the WHO International Registry of Clinical Trials and OpenGrey were also searched.  
 
Study Identification 
Studies were eligible for inclusion if they were a full-text article that satisfied all of the following:  
1) 100 or more participants analysed in the study (to increase power for comparisons);  
2) convincing definition of OA using American College of Rheumatology criteria (14), based on 
symptoms of sustained pain and stiffness in the affected joint, radiographic changes 
including osteophytes, cartilage loss, bone cysts/sclerosis and joint space narrowing, with 
normal inflammatory markers;  
3) abstract/title that must refer to pain and/or structure in relation to OA as a primary disease;  
4) Knee or hip OA;  
5) pain and/or function scores;  
6) joint imaged and  
7) minimum six-month follow-up of pain/function outcome measures.  
Non-English studies, letters, conference articles and reviews were excluded. 
 
The titles and abstracts were reviewed by one reviewer (SS). The full-text for each paper was 
assessed for eligibility by one reviewer (SS) and double-checked by a second (TS). Any disagreements 
were addressed through discussion and adjudicated by a third reviewer (NS or FH). All studies which 
satisfied the criteria were included in the review. 
 
Quality Assessment 
To assess the risk of bias and the power of the methodology, the Downs & Black (D&B) tool was 
applied (15). These tools assessed the following aspects of each study: reporting quality, external 
validity, internal validity- bias, selection bias and power. The modified D&B tool was used. 
Accordingly, the 27-item randomised controlled trial (RCT) version was used for RCTs whilst the 18-
item non-RCT version was used for non-RCT designs (Supplementary File 2). Both 18-item and 27-
item tools have been demonstrated to be valid and reliable tools to assess RCT and non-RCT papers 
(14). Critical appraisal was performed by one reviewer (SS) and verified by a second (KT). Any 
disagreements were dealt with by discussion and adjudicated through a third reviewer (TS). In 
previous literature D&B score ranges were given corresponding quality: excellent (26-28); good (20-
25); fair (15-19); and poor (<14) (14). Item 4 on the non-RCT and Item 5 from the RCT tool are scored 
two points, hence the total scores equate to 19 and 28 points respectively. The D&B tool was used 
to exclude poor quality studies with a score 15/28 or lower in RCTs and 10/19 or lower in non-RCTs.  
 
Data Extraction 
Data were extracted including: subject demographic data, study design, pain and function outcome 
measures, imaging used, OA severity scores, change in pain and function outcomes and change in 
OA severity scores. After all relevant data had been extracted, authors of these papers were 
approached to try and attain individual patient data (IPD) related to baseline and change in pain, 
function and structural scores for each study. No data was received from authors to inform this 
analysis.  
 
Outcomes 
The primary outcome was to determine the development of pain and functional impairment for 
those with knee and hip OA. The secondary outcome was to determine which factors are associated 
with structural changes in knee and hip OA. 
 
Data Analysis 
All data were assessed for study heterogeneity through scrutiny of the data extraction tables. These 
identified that there was minimum study-based heterogeneity based on: population, study design 
and interventions-exposure variabilities for given outcomes. Where there was study heterogeneity, a 
narrative analysis was undertaken. In this instance, the odds ratio (OR) of all predictor variables were 
tabulated with a range of OR presented. Where there was sufficient data to pool (two or more 
studies with data available to analyse) and study homogeneity evident, a pooled meta-analysis was 
deemed appropriate. As interpreted by the Cochrane Collaboration (16), when I2 was 50% or greater 
representing high-statistical heterogeneity, a random-effects model meta-analysis was undertaken. 
When I2 was less than this figure, a fixed effects model approach was adopted. Continuous 
outcomes were assessed using mean difference (MD) scores of measures for developing severe OA, 
whereas dichotomous variables were assessed through OR data. All data were presented with 95% 
confidence intervals (CI) and forest-plots.  
 
Due to the presentation of the data, there were minimal data to permit meta-analyses. Where there 
was insufficient data to pool the analysis (data only available from one study), a narrative analysis was 
undertaken to assess risk factors for the development of increased pain and functional impairment. 
Planned subgroup analyses included determine whether there was a difference in risk factors based 
on: (1) anatomical regions (i.e. difference between hip OA and knee OA); (2) geographical region. 
Analyses were undertaken on STATA version 14.0 (Stata Corp, Texas, USA) with forest plots 
constructed using RevMan Review Manager (RevMan) [Computer program]. Version 5.3. 
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.) 
 
RESULTS 
 
Search Strategy 
The results of the search strategy are presented in Figure 1. In total, 11,010 citations were identified. 
Of these, 141 papers were deemed potentially eligible and screened at full-text level. Of these, 82 
met the selected criteria and were included. 
 
Characteristics of Included Studies 
A summary of the included studies is presented as Table 1. This consisted of 31 non-RCTs (27 
observational cohort studies/four case-control studies) and 51 RCTs.  
 
In total, 45,767 knees were included in the analysis. This consisted of 13,870 males and 23,497 
females; four studies did not report the gender of their cohorts (17,18,19,20). Thirty-six studies were 
undertaken in the USA; 30 were undertaken in Europe; nine were conducted in Australasia and 
seven in Asia. Mean age of the cohorts was 61.7 years (standard deviation (SD): 7.56); 36 studies did 
not report age (17,21,22-54). Mean follow-up period was 35.4 months (SD: 33.6). The most common 
measures of pain were WOMAC pain (n=55; 50%) and Visual Analogue Scale (VAS) Pain (n=21; 19%). 
The most frequently used measures of function were WOMAC function (n=52; 44%), physical tests 
(n=16; 14%) and SF-36 (n=10; 9%). 
 
Methodological Quality Assessment 
The methodological quality of the evidence was moderate (Supplementary File 2; Supplementary 
File 3). Based on the results of the D&B non-RCT tool (31 studies; Supplementary File 2), recurrent 
strengths of the evidence were clear description of the participants recruited (29 studies; 94%), the 
representative nature that participants were to the population (31 studies; 100%), and variability in 
data presented for the main outcomes (31 studies; 100%). Furthermore the main outcome measures 
were deemed reliable and valid in all studies (31 studies; 100%) with 89% (27 studies; 87%) studies 
adopting appropriate statistical analyses for their datasets. Recurrent limitations were not clearly 
reporting the main findings (20 studies; 65%), issues regarding the representation of the cohort from 
the wider public (18 studies; 58%) and only six studies (19%) basing their sample sizes on an a prior 
power calculation.  
 
The results from the D&B RCT checklist (51 studies; Supplementary File 3) similarly reported findings 
with strength of the evidence around clear reporting of the cohort characteristics (49 studies; 96%) 
and interventions (50 studies; 98%), adoption of reliable/valid outcome measures (51 studies; 100%) 
and reported high compliance to study processes (37 studies; 73%). Recurrent weaknesses included 
recruiting cohorts which may not have been reflective of the wider population (19 studies; 37%), in 
clinic settings which may not have represented typical clinical practice (21 studies; 41%) and poorly 
adjusting for potential confounders in analyses (26 studies; 51%). 
Knee OA  
 
Narrative Review  
Findings from the narrative analysis found the following were predictors for worsening joint pain: 
KL3 or 4 in women (OR: 11.3; 95% CI: 6.2 to 20.4), a WORMS lateral meniscal cyst (MC) score of 1 
(OR: 4.3; 95% CI: 1.2 to 15.4), presence of chronic widespread pain (CWP) (OR: 3.2; 95% CI: 1.9 to 
5.3), increase of ≥2 in WORMS BML score after 15 months (OR: 3.2; 95% CI: 1.5 to 6.8), meniscal 
maceration (OR: 2.8; 95% CI: 1.8 to 4.4) or damage ≥2 in WORMS (OR: 1.8; 95% CI: 0.9 to 3.6). We 
also found the following were the highest predictors of worsening function in people with knee OA: 
KL of <3 (OR: 3.3; 95% CI: 0.7 to 15.9), modified KL 3a (OR: 1.7; 95% CI: 0.7 to 3.8), modified KL 4a 
(OR: 1.5; 95% CI: 0.7 to 3.0), presence of osteophytes (OR: 1.3; 95% CI: 0.7 to 2.4), female gender 
(OR: 1.8 (95% CI: 1.1 to 3.0) to OR: 2.1 (95% CI: 1.2 to 3.5)), ethnicity (OR: 1.03; 95% CI 0.59 to 1.83) 
and synovitis ≥1 (OR: 1.3; 95% CI: 0.8 to 1.9). 
 
Meta-Analysis 
Two studies were identified where data could be evaluated for OA risk factors by meta-analysis 
(41,67). Three variables significantly associated with the development of knee OA. As illustrated in 
Table 2 and Figures 2a-d, age (MD: 1.46, 95% CI: 0.26 to 2.66; p=0.02; N=823), KL of ≥ 2(MD: 2.04, 
95% CI: 1.48 to 2.81; p<0.01; N=823) and knee effusion score ≥1 (OR: 1.35, 95% CI: 0.99 to 1.83: 
p=0.05; N=823) were all associated with the development of knee OA based on moderate quality 
evidence. The variables of gender and BMI were not shown to be significantly associated with the 
knee OA development (Table 2).   
 
Due to the limited availability of data it was not possible to conduct the planned subgroup analyses 
to determine whether there was a difference in risk factors based on anatomical or geographical 
regions. 
Hip OA  
 
Narrative Analysis 
This was based on low-quality evidence. There was no association between the development of hip 
BML and BMI or age. Predictors for worsening joint pain for people with hip OA included a large 
acetabular BML (OR: 5.2; 95% CI: 1.2 to 22.9), a large femoral head BML (OR: 4.4; 95% 1.4 to 19.7) 
with any large hip BML (OR: 4.4; 95% CI: 1.5 to 13.2), CWP (OR: 5.0; 95% CI: 2.8 to 9.1) and 
depression (OR: 1.9; 95% CI: 1.2 to 2.9). Baseline knee pain score (MD:-1.4; 95% CI: -1.6 to -1.2) and 
baseline hip pain score (MD:-0.7; 95% CI: -1.0 to -0.5) were significantly associated with the 
development of hip BMLs and pain. 
 
Meta-Analysis 
There were insufficient data to permit meta-analysis for the hip OA dataset. 
 
DISCUSSION 
 
Our systematic review and meta-analysis identified risk factors for knee and hip OA pain and 
structural damage based on evaluation of 82 studies. For the knee, increasing pain in knee OA was 
associated with KL grade 3 or 4 in women, WORMS lateral MC, presence of CWP, increase of ≥2 in 
WORMS BML score after 15 months and meniscal maceration. In addition, KL<3, KL 3a, KL 4a, 
osteophyte presence and female gender were associated with worsening function in people with 
knee OA. On meta-analysis, age, radiological features (KL score of 2 or more) and knee effusion were 
associated with development and/or progression of knee OA.   
 
Our meta-analysis identified risk factors that are appreciated only when results were pooled 
together. These were namely WORMS-defined knee effusion score ≥1. To our knowledge, this is the 
currently the largest and most up to date systematic review of its kind, reviewing 82 primary studies 
in 41,810 participants. Nonetheless, some risk factors from our meta-analysis have been recognised 
previously. For example, Silverwood et al. reported previous injuries are associated to developing 
knee OA, supporting the present analysis (95). Kingsbury et al. identified age and KL grade as 
predictive factors for developing knee OA, supporting the present findings (96). Therefore the meta-
analyses provided both novel and supporting findings for risk factors associated with developing and 
progressing knee OA. A machine learning study assessed risk factors associated with pain and 
radiological progression in knee OA found that BMLs, osteophytes, medial meniscal extrusion, 
female gender and urine CTX-II contributed to progression (95). Nelson et al’s. work is supported by 
other studies (95,96). Therefore the findings of this analysis support previous findings.  
 
After plain radiography, MRI was the most used modality with WORMS as the commonest scoring 
reported for MRI. The MRI Osteoarthritis Knee Score (MOAKS) (98), expanded on WORMS by scoring 
entire sub-regions for BMLs rather than each BML, further division of cartilage regions and refined 
the features assessed in meniscal morphology.  Due to this progression from WORMS, having no 
MOAKS studies included in our final selection was surprising. This could be due to the eligibility 
criteria being too restrictive. A future systematic review and meta-analysis focusing on the imaging 
aspect of evaluating OA will be important. In hip OA, the evaluation of BML size and location is 
essential in predicting pain progression and these can be assessed effectively using MRI. We 
recommend that all MRI studies for hip OA evaluate BML size and location.  
 
Gait analysis is considered a risk factor for pain/function and was therefore included as a target 
outcome measure. However, few studies included gait analysis measures, which could not be 
included in the analysis, perhaps due to the minimum sample size (n=100) being too restrictive.  
 
There were several limitations within our study. Firstly, despite identifying novel risk factors for 
exhibiting knee OA, a small dataset was pooled together for the meta-analysis (two studies) 
compared to Silverwood et al. (34 studies) (93).  This was particularly apparent for hip OA where 
only 12 studies assessed this population (8,17,23,30,46,47,48,50,54,71,76,94). Consequently the 
small dataset influenced the GRADE assessment that determined the evidence as low to moderate, 
restricting the strength of the associations of risk factors with OA development and progression. 
Further work may impact our confidence in the estimated effect, for both studies recruiting 
participants with hip and knee OA. Secondly, the eligibility criteria may have been too restrictive, 
resulting in limited papers including gait analysis or MOAKS. Wet biomarkers were not included in 
our analyses. Finally, the inability to pool data was partly attributed to variability in methods to 
report data.  Standardising data collection and reporting is important in conducting meta-analyses. 
We believe the following should be undertaken to improve data pooling in future work: ensuring 
group comparisons in studies are selected from the same population (people with confirmed OA) to 
improve internal validity, observational studies should conduct a power analysis to determine 
sample sizes and all studies should include absolute frequency of events data rather than summary 
odds ratios. Such considerations will improve future meta-analyses to identify OA risk factors.  
 
To conclude, our work helps to develop steps towards building a stratification tool for risk factors for 
knee OA pain and structural damage development. We also highlight the need for collection of core 
datasets based on defined domains, that has recently also been highlighted by the OMERACT-OARSI 
core domain set for knee and hip OA (13). Collection of future datasets based on standardised core 
outcomes will assist in more robust identification of risk factors for large joint OA. 
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Table 1: Characteristics of included studies 
 Study 
Design 
Number 
joints 
(hip/kne
es) 
Gender 
(male:fem
ale) 
Country 
origin 
Mea
n age 
(year
s) 
Follow
-up 
durati
on 
(mont
hs) 
Pain 
outcome 
measure
s 
Function
al 
outcome 
measure
s 
Ahedi 2014 
(54) 
Observatio
nal cohort 
198 hips 111:87 Australia UTD 132 WOMAC 
Pain  
NA 
Akelman 
2016 (20) 
RCT 107 knee UTD USA 23.5 84 KOOS 
pain; SF-
36 Body 
pain 
SF-36 
Physical; 
AP laxity; 
IKDC200
0 
Amin 2008 
(55) 
Observatio
nal cohort 
265 
knees 
152:113 USA 67 30 VAS Pain WOMAC 
Function 
Antony 2017 
(56) 
Observatio
nal cohort 
463 
knees 
245:218 USA 63 24 WOMAC 
Pain 
NA 
Arden 2016 
(57) 
RCT 474 
knees 
185:289 UK 64 36 WOMAC 
Pain 
WOMAC 
Function 
Ayral 2003 
(58) 
RCT 665 
knees 
259:406 Australia, 
Belgium, 
Canada, 
Denmark
, Finland, 
France, 
Hungary, 
Norway, 
Spain,  
United 
Kingdom 
U.S.A. 
61.3 12 WOMAC 
Pain 
WOMAC 
Function 
Baselga 
Garcia-
Escudero 
2015 (59) 
Observatio
nal cohort 
118 
knees 
43:75 Spain 59.1 24 NRS; 
WOMAC 
Pain 
WOMAC 
Function 
Bevers 2015 
(60) 
Observatio
nal cohort 
125 
knees 
57:68 Netherla
nds 
57 24 WOMAC 
Pain 
WOMAC 
Function 
Bingham 
2006 (53) 
RCT 2483 
knees 
735:1748 USA 
Canada 
Austria 
Czech 
Republic 
France 
Germany 
Hungary 
Ireland 
Italy 
Netherla
nds 
Poland 
Croatia 
UTD 24 WOMAC 
Pain 
WOMAC 
Function 
Birmingham 
2009 (61) 
Observatio
nal cohort 
126 
knees 
100:26 Canada 47.5 24 KOOS 
Pain 
KOOS 
Function; 
SF-36 
Physical; 
LEFS 
Bisicchia 
2016 (52) 
RCT 150 
knees 
47:103 Italy UTD 12 VAS Pain; 
SF-36 
SF-36 
Brandt 2005 
(62) 
RCT 431 
knees 
0:431 USA 54.9 30 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function 
Brown 2012 
(51) 
RCT 690 
knees 
270:420 USA UTD 32 
weeks 
WOMAC 
Pain; NRS 
weekly 
pain 
WOMAC 
Function; 
SF-36 
Function 
Brown 2013 
(50) 
RCT 621 hips 237:384 USA UTD 32 
weeks 
WOMAC 
Pain 
WOMAC 
Function 
Bruyere 
2004 (63) 
RCT 319 knee 0:319 Belgium 64.0 36 WOMAC 
Pain 
WOMAC 
Function 
Campbell 
2006 (49) 
RCT 100 
knees 
28:72 Australia UTD 120 American 
Knee 
Society 
Score; 
WOMAC 
Pain 
American 
Knee 
Society 
Score 
(function
); 
WOMAC 
Function 
Chandraseka
ran 2016A 
(48) 
Case-
Control 
111 hips 66:45 USA UTD 24 Modified 
Harris 
Hip 
Score; 
Nonarthr
itic hip 
score; 
VAS Pin 
Modified 
Harris 
Hip 
Score; 
Nonarthr
itic hip 
score; 
Hip 
Outcome 
Score; 
Sports & 
ADLs 
Chandraseka
ran 2016B 
(47) 
Case-
Control 
186 hips 96:90 USA UTD 24 Modified 
Harris 
Hip 
Score; 
Nonarthr
itic hip 
score; 
VAS Pin 
Modified 
Harris 
Hip 
Score; 
Nonarthr
itic hip 
score; 
Hip 
Outcome 
Score; 
Sports & 
ADLs 
Conrozier 
2016 (64) 
RCT 205 
knees 
88:117 France 65 26 WOMAC 
Pain; NRS 
walking 
pain 
WOMAC 
Function 
Davis 2017 
(19) 
Case-
control 
3132 
knees 
UTD USA UTD 48 WOMAC 
Pain; 
KOOS 
Pain 
WOMAC 
Function  
Dougados 
2001 (46) 
RCT 507 hips 202:305 France UTD 36 VAS Pain Lequesne 
Index 
Dowsey 
2012 (65) 
Observatio
nal cohort 
478 
knees 
147:331 Australia 70.8 24 IKSS Pain IKSS 
Function 
Eckstein 
2013 (45) 
RCT 1412 
knees 
611:801 Austria UTD 48 WOMAC 
Pain 
NA 
Ettinger 
1997 (44) 
RCT 439 
knees 
131:308 USA UTD 18 Pain 
intensity 
score 
Physical 
Test 
Felson 2013 
(66) 
Observatio
nal cohort 
3498 
knees 
867:1206 USA 61.2 30 WOMAC 
Pain 
PASE 
Felson 2007 
(67) 
Observatio
nal cohort 
330 
knees 
111:2111 USA 62.1 15 NA Quadrice
ps 
strength 
(N) 
Filardo 2015 
(43) 
RCT 183 
knees 
112:71 Italy UTD 48 KOOS 
Pain; 
IKDC 
KOOS 
Function; 
Tegner; 
IKDC 
Glass 2013 
(42) 
Observatio
nal cohort 
4648 
knees 
918:1486 USA UTD 24 WOMAC 
Pain; NRS 
Pain 
WOMAC 
Function 
Guermazi 
2010 (41) 
Case-
control 
493 
knees 
185:308 USA UTD 60 WOMAC 
Pain 
PASE 
Hamilton 
2017 (68) 
Observatio
nal cohort 
805 
knees 
416:289 UK 66 30 WOMAC 
Pain 
WOMAC 
Function 
Hellio le 
Graverand 
2013 (69) 
RCT 1457 
knees 
343:1114 USA 
Canada 
Australia, 
Belgium, 
Czech 
Republic, 
Germany
, 
Hungary,  
Italy, 
Poland, 
Russian 
Federatio
n, 
Slovakia, 
Spain, 
Argentin
a  
Peru 
61.0 180 Oxford 
Knee 
Score 
Oxford 
Knee 
Score; 
American 
Knee 
Society 
Score; 
Tegner 
Henriksen 
2013 (40) 
RCT 157 
knees 
28:129 Denmark UTD 24 WOMAC 
Pain 
WOMAC 
Function 
Hill 2016 (5) RCT 202 
knees 
102:100 Australia 61 12 KOO Pain KOOS 
Function 
and 
kinemati
c 
assessme
nt 
Hochberg 
2016 (70) 
RCT 522 
knees 
84:438 France 
Germany 
62.7 24 WOMAC 
Pain 
WOMAC 
Function 
Poland 
Spain 
Hoeksma 
2004 (71) 
RCT 109 hips 33:76 Netherla
nds 
72 6 WOMAC 
Pain; 
Huskisso
n’s VAS; 
EQ-5D 
Pain 
WOMAC 
Function; 
EQ-5D 
Function 
Housman 
2014 (39) 
RCT 391 
knees 
130:261 USA 
Canada 
France 
UK 
Germany 
UTD 6 SF-36 
Body 
Pain; 
Harris 
Hip 
Score; 
VAS Pain 
SF-36 
Function; 
Harris 
Hip 
Score; 
ROM 
Huang 2003 
(72) 
RCT 264 
knees 
39:93 Taiwan 62 6 WOMAC 
Pain 
NA 
Huizinga 
2017 (73) 
Observatio
nal cohort 
298 
knees 
201:97 Netherla
nds 
51 12 VAS Pain Lequesne 
index; 
Walking 
speed 
Jin 2016 (6) RCT 413 
knees 
205:208 Australia 63.2 24 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function 
Kahn 2013 
(74) 
Observatio
nal cohort 
174 
knees 
70:102 USA 67.0 6 WOMAC 
Pain 
WOMAC 
Function 
Karsdal 2015 
(38) 
RCT 2207 
knees 
773:1424 Denmark UTD 24 WOMAC 
Pain 
WOMAC 
Function 
Katz 2013 
(37) 
RCT 330 
knees 
143:187 USA UTD 12 KOO Pain WOMAC 
Function; 
SF-36 
Function 
Kim 2017 
(75) 
RCT 352 
knees 
9:153 Republic 
of Korea 
68.1 144 WOMAC Knee 
Society 
Knee 
Score 
Function; 
ROM; 
UCLA 
Activity 
Kinds 2012 
(18) 
RCT 565 
knees 
UTD Netherla
nds 
UTD 60 WOMAC 
Pain 
WOMAC 
Function 
Kongtharvon
skul 2016 
(36) 
RCT 148 
knees 
25:123 Thailand UTD 6 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function 
Lequesne 
2002 (76) 
RCT 163 hips 102:61 France 63.2 24 VAS Pain Lequesne 
Index 
Lohmander 
2014 (35) 
RCT 170 
knees 
52:116 Bulgaria 
Canada 
Croatia 
Finland 
Germany 
Poland 
Serbia 
Africa 
Sweden 
UTD 12 WOMAC 
Pain 
WOMAC 
Function 
USA 
 
Maheu 2014 
(8) 
RCT 345 hips 159:186 France 62.2 36 WOMAC 
Pain; 
Global 
Hip Pain 
Lequesne 
Index; 
WOMAC 
Function; 
Global 
handicap 
NRS 
Marsh 2016 
(34) 
RCT 168 
knees 
57:112 Canada UTD 24 WOMAC WOMAC 
McAlindion 
2013 (33) 
RCT 146 
knees 
57:89 USA UTD 24 WOMAC 
Pain  
WOMAC 
Function; 
Physical 
Test 
Messier 
2004 (32) 
RCT 316 
knees 
89:227 USA UTD 18 WOMAC 
Pain 
WOMAC 
Function; 
Physical 
Test 
Messier 
2005 (77) 
RCT 142 
knees 
37:105 USA 68.5 18 WOMAC 
Pain 
WOMAC 
Function; 
Physical 
Test 
Messier 
2013 (78) 
RCT 454 
knees 
128:325 USA 66 18 WOMAC 
Pain 
WOMAC 
Function; 
Physical 
Test; SF-
36 
Physical 
Michel 2005 
(31) 
RCT 300 
knees 
146:154 Switzerla
nd 
UTD 24 WOMAC 
Pain 
WOMAC 
Function; 
Physical 
Test 
Muraki 2014 
(79) 
Observatio
nal cohort 
1558 
knees 
553:1005 Japan 67.0 40 WOMAC 
Pain 
WOMAC 
Function;  
Muraki 2015 
(80) 
Observatio
nal cohort 
1525 
knees 
546:979 Japan 67.0 40 WOMAC 
Pain 
WOMAC 
Function 
Pavelka 2000 
(30) 
RCT 277 
knees; 
117 hips 
109:285 Czech 
Republic 
58 60 NA Lequesne 
Index 
Pavelka 2002 
(81) 
RCT 202 
knees 
45:157 Czech 
Republic 
UTD 36 WOMAC 
Pain 
WOMAC 
Function; 
Lequesne 
Index 
Pham 2004 
(29) 
Observatio
nal cohort 
301 
knees 
97:204 France UTD 12 VAS Pain Lequesne 
Index 
Podsiadlo 
2014 (28) 
Observatio
nal cohort 
114 
knees 
49:65 Australia UTD 72 WOMAC 
Pain 
WOMAC 
Function 
Rat 2011 
(82) 
RCT 300 
knees 
118:182 France 67 6 SF-36 
Body 
Pain; 
OAKHQO
L Pain; 
VAS Pain 
Lequense 
Index; 
SF-36 
Physical; 
OAKHQO
L Physical 
Activity 
Raynauld 
2011 (27) 
RCT 123 
knees 
44:79 Canada UTD 24 WOMAC 
Pain 
WOMAC 
Function 
Reginster 
2001 (26) 
RCT 212 
knees 
50:162 Belgium UTD 36 WOMAC 
Pain 
WOMAC 
Function 
Reginster 
2013 (83) 
RCT 1371 
knees 
425:946 Australia 
Austria 
Belgium 
Canada 
Czech 
Republic 
Denmark 
Estonia 
France 
Germany 
Italy 
Lithuania 
Netherla
nds 
Poland 
Portugal 
Romania 
Russian 
Federatio
n 
Spain 
United 
Kingdom 
 
62.9 36 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function 
Riddle 2015 
(25) 
Observatio
nal cohort 
467 
knees 
209:258 USA UTD 24 KOOS 
Pain 
WOMAC 
Function 
Romagnoli 
2017 (84) 
Observatio
nal cohort 
105 
knees 
16:69 Italy 67.7 66 Knee 
Society 
Score 
Clinical; 
VAS Pain 
Knee 
Society 
Score 
Function; 
ROM 
Roman-Blas 
2017 (24) 
RCT 158 
knees 
26:132 Spain UTD 6 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function 
Rozendaal 
2008 (31) 
RCT 222 hips 68:154 Netherla
nds 
UTD 24 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function 
Sanchez-
Ramirez 
2015 (85) 
Observatio
nal cohort 
186 
knees 
59:127 Canada 61 24 WOAMC 
Pain 
WOMAC 
Function; 
Physical 
Test 
Sawitzke 
2010 (86) 
RCT 662 
knees 
215:447 USA 57 24 WOMAC 
Pain 
WOMAC 
Function 
Skou 2016 
(87) 
Observatio
nal cohort 
1682 
knees 
434:818 Denmark 62.2 84 WOMAC 
Pain 
PASE; 
Physical 
Test 
Sowers 2011 
(88) 
Observatio
nal cohort 
724 
knees 
0:363 USA 56 132 NA WOMAC 
Function; 
Physical 
Test 
Spector 2005 
(89) 
RCT 284 
knees 
115:169 UK 63.3 12 WOMAC 
Pain 
WOMAC 
Function 
Sun 2017 
(90) 
RCT 121 
knees 
31:90 Taiwan 63 6 WOMAC 
Pain; VAS 
Pain 
WOMAC 
Function; 
Lequesne 
Index; 
Physical 
Test 
Urish 2013 
(22) 
RCT 336 
knees 
96:67 USA UTD 36 WOMAC WOMAC 
Valdes 2012 
(17) 
Observatio
nal cohort 
860 
knees; 
928 hips 
UTD UK UTD 38 WOMAC 
Pain 
NA 
Van der Esch 
2016 (99) 
Observatio
nal cohort 
402 
knees 
64:137 Netherla
nds 
61.2 24 NRS Pain WOMAC 
Function; 
Physical 
Test 
Weng 2009 
(91) 
RCT 264 
knees 
26:106 Taiwan 64 12 VAS Pain Lequesne 
Index; 
ROM; 
Physical 
Test 
White 2016 
(92) 
Observatio
nal cohort 
2110 
knees 
992:118 USA 61.0 84 VAS Pain WOMAC 
Function 
Witt 2005 
(93) 
RCT 294 
knees 
70:154 Germany 64.0 12 WOMAC 
Pain; SF-
36 Body 
Pain; VAS  
Pain 
WOMAC 
Function; 
SF-36 
Function 
Yu 2016 (21) Observatio
nal cohort 
204 
knees 
74:130 Australia UTD 12 KOOS 
Pain; VAS 
Pain 
KOOS 
ADL; 
Physical 
Function 
Yusuf 2011 
(94) 
Observatio
nal cohort 
74 
knees; 
31 hips; 
11 hip 
and 
knees 
19:98 Netherla
nds 
60 72 WOMAC 
Pain; SF-
36 Body 
Pain; 
Pain on 
moveme
nt 
WOMAC 
Function; 
SF-36 
Function; 
Physical 
Test 
ADLs – Activities of Daily Living; IKDC - International Knee Documentation Committee; KOOS - Knee Injury and 
Osteoarthritis Outcome Score;  LEFS – Lower Extremity Functional Scale; NA – not applicable; NRS – numerical 
rating scale; PASE – Physical Activity Scale for the Elderly; RCT – randomised controlled trial; ROM – range of 
motion; OAKHQOL  - osteoarthritis knee and hip quality of life questionnaire; SF-36 – Short Form-36; UCLA 
Activity - UK – United Kingdom; USA - United States of America; UTD – unable to determine; VAS – visual 
analogue scale; WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index 
 
  
Table 2. Meta-Analysis Results: Exhibit Knee OA 
 
 
 
 
BMI – body mass index; KL – Kellgren Lawrence scale; I2 – inconsistency-squared; N- number of 
participants in analysis; NE – not estimable 
* - random effects model analysis 
1GRADE – Outcomes downgraded one level due to risk of bias, two level due to imprecision and 
inconsistency; 2GRADE – Outcomes downgraded one level due to risk of bias
Variable N Effect Estimate P-
Value 
Statistical 
Heterogeneity 
(I2%) 
GRADE Assessment 
Gender 823 0.91 (0.48 to 1.72)* 0.78 87 Low quality evidence1 
Age 823 1.46 (0.26 to 2.66) 0.02 0 Moderate quality evidence2 
KL ≥2 823 2.04 (1.48 to 2.81)  <0.01 35 Moderate quality evidence2 
Knee effusion score 
≥1 
823 1.35 (0.99 to 1.83) 0.05 0 Moderate quality evidence2 
BMI 823 -0.08 (-0.75 to 0.58) 0.81 0 Moderate quality evidence2 
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Figure and Table Legends 
 
Figure 1: PRISMA flow-chart 
 
Figure 2a: Forest-plot to present the association between gender and presentation of knee OA. 
Figure 2b: Forest-plot to present the association between age and presentation of knee OA. 
Figure 2c: Forest-plot to present the association between knee effusion score greater or equal to 1 
and presentation of knee OA. 
Figure 2d: Forest-plot to present the association between BMI and presentation of knee OA. 
 
Table 1: Characteristics of included studies 
 
Supplementary File 1: Search strategy adopted for the EMBASE database search. 
 
Supplementary File 2: Methodological appraisal results based on the Downs and Black non-RCT 
Checklist 
 
Supplementary File 3: Methodological appraisal results based on the Downs and Black RCT Checklist  
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Figure 1: PRISMA flow-chart 
 
 
 
 
  
38 
 
Figure 2a: Forest-plot to present the association between gender and presentation of knee OA. 
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Figure 2b: Forest-plot to present the association between age and presentation of knee OA. 
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Figure 2c: Forest-plot to present the association between knee effusion score greater or equal to 1 
and presentation of knee OA. 
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Figure 2d: Forest-plot to present the association between BMI and presentation of knee OA. 
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Supplementary File 1: Search strategy adopted for the EMBASE database search. 
 
 
 
  
1     exp arthritis/  
2     exp osteoarthritis/  
3     exp joint diseases/  
4     exp arthropathy/  
5     exp arthralgia/  
6     exp joint pain/  
7     exp chronic pain/  
8     exp gonarthrosis/  
9     exp osteoarthrosis/  
10     exp degenerative arthritis/  
11     (degenerative adj2 arthritis).tw.  
12     or/1-11  
13     (Hip adj2 Joint).mp.  
14     (Knee adj2 Joint).mp.  
15     or/13-14  
16     and/12,15  
17     Imaging.tw.  
18     Radiography.tw.  
19     Radiology.tw. 
20     Magnetic resonance imagining.tw.  
21     MRI.tw.  
22     Computed Tomography.tw.  
23     CT.tw.  
24     Ultrasound.tw.  
25     US.tw.  
26     USS.tw.  
27     Sonography.tw. 
28     X-ray.tw.  
29     Radiograph.tw. 
30     PET.tw.  
31     Bone marrow lesions.tw.  
32     BML.tw.  
33     cytokines.tw.  
34     extracellular matrix degradation.tw.  
35     ECM degradation.tw. 
36     GWAS.tw.  
37     cartilage.tw. 
38     serum.tw.  
39     synovitis.tw. 
40     or/17-39  
41     exp pain/  
42     exp peripheral nervous system disease/  
43     exp somatosensory disorders/  
44     ((pain* or discomfort*) adj10 (central or complex or nerv* or neuralg* or neuropath*)).mp. 
45     ((neur* or nerv*) adj6 (compress* or damag*)).mp. 
46     WOMAC.tw.  
47     McGill.tw.  
48     VAS.tw.  
49     Visual analogue.tw.  
50     NRS.tw.  
51     Numerical rating scale.tw.  
52     Analgesic.tw.  
53     Analgesia.tw.  
54     or/41-53  
55     or/40,54  
56     and/16,55  
57     limit 56 to English language  
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Supplementary File 2: Methodological appraisal results based on the Downs and Black non-
RCT Checklist 
 Downs and Black Non-Randomised Controlled Trial Checklist Items 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Total 
Ahedi (54) 1 1 1 0 1 1 0 1 1 1 1 UC 1 1 1 UC 1 0 13 
Amin (55) 1 1 0 1 1 1 1 0 0 UC 1 1 1 1 UC 1 1 0 12 
Antony (560 1 1 1 2 1 1 1 0 1 0 UC UC 1 1 1 UC 1 0 13 
Baselga Garcia-
Escudero (59) 1 1 1 0 1 1 1 1 
UC UC 1 1 1 1 UC 0 1 1 13 
Bevers (60) 1 1 1 2 0 1 1 1 UC 0 1 1 1 1 1 1 1 0 15 
Birmingham 
(61) 1 1 1 1 1 1 1 1 1 1 UC 1 1 UC 1 1 1 0 15 
Chandrasekaran 
(48) 1 1 1 1 1 1 1 1 0 
UC 1 1 1 1 UC 1 1 1 15 
Chandrasekaran 
(47) 1 1 1 1 1 1 0 1 0 
UC 1 1 1 1 UC 1 UC 1 13 
Davis (19) 1 1 1 0 0 1 1 0 1 1 1 UC 1 1 1 UC 1 0 12 
Dowsey (65)  1 1 1 1 1 1 1 1 1 1 1 UC 1 1 1 1 1 0 16 
Felson (66) 1 1 1 1 0 1 1 1 0 UC 1 1 1 UC 1 1 1 0 13 
Felson (67) 1 1 1 1 0 1 1 1 0 UC 1 1 1 UC 1 1 1 0 13 
Glass (42) 1 1 1 2 0 1 1 1 1 1 1 1 1 1 1 1 1 0 17 
Guermazin (41) 1 1 1 2 0 1 1 1 1 1 1 1 1 UC 1 1 1 0 16 
Hamilton (68) 1 1 0 0 1 1 1 1 UC UC 1 1 1 1 UC UC 1 1 12 
Huizinga (73) 1 1 1 0 1 1 1 0 UC UC 1 1 1 1 UC 0 1 0 11 
Khan (74) 1 1 1 1 0 1 1 1 1 1 0 1 1 UC 1 1 1 0 14 
Muraki (79) 1 1 1 1 1 1 1 1 1 UC 1 1 1 1 0 1 1 0 15 
Muraki (80) 1 1 1 2 1 1 1 1 1 UC 1 1 1 1 0 1 1 0 16 
Pham (29) 1 1 1 1 1 1 1 1 UC UC 1 1 1 0 1 1 1 0 14 
Podsiadlo (28) 1 1 1 1 0 1 1 1 UC UC 1 1 1 UC UC 1 1 0 12 
Riddle (25) 1 1 1 2 1 1 0 0 1 1 0 1 1 1 1 1 1 1 16 
Romagnoli (84) 1 0 1 0 0 1 1 1 1 1 1 1 1 UC 1 UC 1 1 13 
Sanchez-
Ramirez (85) 1 1 1 2 1 1 1 1 1 1 1 1 1 
UC 1 1 1 0 17 
Skou (87) 1 1 1 2 0 1 1 1 1 1 1 1 1 UC 1 1 1 0 16 
Sowers (88) 1 1 1 0 1 1 1 1 1 UC 1 1 1 UC 1 0 0 0 12 
Valder (17) 1 1 1 1 1 1 0 1 UC UC 1 1 1 0 1 1 0 0 12 
Van der Esch 
(99) 1 1 1 1 1 1 1 1 1 1 1 1 1 UC 1 0 1 0 15 
White (92) 1 1 1 2 0 1 1 0 1 1 1 1 1 1 0 1 1 0 15 
Yu (21) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 17 
Yusuf (94) 1 1 1 1 1 1 1 0 UC UC 1 1 1 UC 1 1 1 0 13 
UC: Unclear; 2: Yes; 1: Yes/partially; 0: No 
 
Checklist items 
1. Is the hypothesis/aim/objective of the study clearly described? 
2. Are the main outcomes to be measured clearly described in the Introduction or Methods 
section?  
3. Are the characteristics of the patients included in the study clearly described? 
4. Are the distributions of principal confounders in each group of subjects to be compared 
clearly described?  
5. Are the main findings of the study clearly described? 
6. Does the study provide estimates of the random variability in the data for the main 
outcomes?  
7. Have the characteristics of patients lost to follow-up been described? 
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8. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main 
outcomes except where the probability value is less than 0.001? 
9. Were the subjects asked to participate in the study representative of the entire population 
from which they were recruited?  
10. Were those subjects who were prepared to participate representative of the entire 
population from which they were recruited? 
11. If any of the results of the study were based on “data dredging”, was this made clear? 
12. Were the statistical tests used to assess the main outcomes appropriate? 
13. Were the main outcome measures used accurate (valid and reliable)? 
14. Were study participants in different groups (trials and cohort studies) or were the cases and 
controls (case-control studies) recruited over the same period of time? 
15. Were the participants in different groups (trials and cohort studies) or were the cases and 
controls (case-control studies) recruited from the same population?  
16. Was there adequate adjustment for confounding in the analyses from which the main 
findings were drawn?  
17. Were losses of patients to follow-up taken into account? 
18. Did the study mention having conducted a power analysis to determine the sample size 
needed to detect a significant difference in effect size for one or more outcome measures? 
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Supplementary File 3: Methodological appraisal results based on the Downs and Black RCT Studies Checklist  
 Downs and Black Randomised Controlled Trial Checklist Items 
1 2 3 4 5 6 7 8 9 1
0 
11 12 13 14 15 16 17 1
8 
19 20 21 22 23 24 25 26 27 Total 
Akelman (20) 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 UC 1 1 26 
Arden (57) 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 UC 1 1 1 1 1 1 1 0 1 UC 23 
Ayral (58) 1 1 1 1 1 1 1 1 1 1 0 UC UC 1 1 1 1 1 1 1 0 1 1 UC UC 1 0 20 
Bingham (53) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 UC 1 1 1 1 1 0 1 0 UC 1 1 0 22 
Bisicchia (52) 1 0 1 1 0 1 1 1 1 1 1 1 1 0 1 UC 1 1 1 1 1 1 1 0 0 1 0 20 
Brandt (62) 1 1 1 1 1 0 1 1 1 1 UC UC UC UC 1 1 1 1 1 1 UC 1 1 UC 0 1 0 18 
Brown (50) 1 1 1 1 1 1 1 1 1 0 UC UC UC 1 1 1 1 1 1 1 UC UC 1 UC UC UC 1 18 
Brown (51) 1 1 1 1 1 1 1 1 1 0 UC UC UC 1 1 1 1 1 1 1 UC UC 1 1 UC 1 1 19 
Bruyere (63) 1 1 1 1 1 0 1 0 1 1 UC UC 1 1 1 1 1 1 UC 1 UC UC 1 UC UC 1 1 18 
Campbell (49) 1 1 1 1 0 0 0 1 1 0 1 UC 1 1 1 1 1 1 1 1 1 1 1 1 UC 1 0 20 
Conrozier (64) 1 1 1 1 0 0 1 1 1 1 UC UC UC 1 1 1 1 0 1 1 0 1 1 1 0 1 UC 18 
Dougados (46) 1 1 1 1 1 1 1 1 1 0 1 0 0 UC UC 1 1 1 1 1 0 UC 1 UC 1 1 UC 18 
Eckstein (45) 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 UC 1 1 1 1 1 0 26 
Ettinger (44) 1 1 1 1 1 0 1 1 1 1 UC UC 0 0 UC 1 1 1 UC 1 0 1 1 1 1 1 1 19 
Filardo (43) 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 25 
Hellio le 
Graverand (69) 1 1 1 1 1 0 1 1 1 1 
UC UC UC UC 1 1 UC 1 1 1 0 UC 1 1 UC 1 0 17 
Henriksen (40) 1 1 1 1 2 1 1 1 0 1 UC UC 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
Hill (5) 1 1 1 1 0 0 1 1 1 1 1 0 UC 1 1 1 1 1 1 1 0 1 1 1 0 1 1 21 
Hochberg (70) 1 1 1 1 1 1 1 1 1 1 UC UC UC 1 UC 1 1 1 UC 1 0 UC 1 1 UC 1 0 18 
Hoeksma (71) 1 1 1 1 0 1 1 1 1 0 1 1 0 0 1 1 1 1 0 1 1 1 1 1 UC 1 1 21 
Housman (39) 1 1 1 1 0 0 1 1 1 0 0 UC 0 1 0 1 1 1 UC 1 0 1 1 UC 0 1 1 16 
Huang (72) 1 1 1 1 0 1 1 0 1 0 UC UC UC UC 1 1 UC 1 1 1 1 UC 1 UC 0 1 1 16 
Jin (6) 1 1 1 1 0 1 1 1 0 1 UC UC 0 1 1 1 1 1 UC 1 0 1 1 1 0 1 0 18 
Karsdal (38) 1 1 1 1 1 0 1 1 1 0 UC UC UC 1 1 1 1 1 0 1 0 UC 1 1 1 1 UC UC 
Katz (37) 1 1 1 1 2 1 1 1 1 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 1 UC 17 
Kim (75) 1 0 1 1 0 1 1 0 1 1 UC UC UC 1 1 1 0 1 1 1 UC 1 1 1 0 1 0 17 
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UC: Unclear; 2: Yes; 1: Yes/partially; 0: No 
 
Checklist items 
1. Is the hypothesis/aim/objective of the study clearly described? 
2. Are the main outcomes to be measured clearly described in the Introduction or Methods section?  
3. Are the characteristics of the patients included in the study clearly described? 
4. Are the interventions of interest clearly described? 
Kinds (18) 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 25 
Kongtharvonskul 
(36) 1 1 1 1 2 1 1 1 0 1 1 
UC 0 1 1 1 1 1 0 1 1 1 1 1 1 1 0 23 
Lequesne (76) 1 1 1 1 1 1 1 1 1 1 UC UC 0 1 1 1 1 1 1 1 0 UC 1 1 1 1 0 21 
Lohmander (35) 1 1 1 1 0 1 1 1 1 1 UC UC 0 1 1 0 1 1 1 1 0 1 1 1 0 1 1 20 
Maheu (8) 1 1 1 1 0 1 0 1 0 1 UC UC 0 1 1 1 1 UC 1 1 0 1 1 1 1 0 0 17 
Marsh (34) 1 1 0 1 2 1 1 0 1 1 UC UC 1 0 0 1 1 1 UC 1 UC UC UC UC 1 1 0 16 
McAlindion (33) 1 1 1 1 1 1 1 1 0 1 0 UC 0 1 1 1 1 1 1 1 0 1 1 1 UC 1 0 20 
Messier (32) 1 1 1 1 1 0 1 1 0 0 0 UC 0 0 1 1 1 1 0 1 UC 1 1 1 1 0 1 17 
Meissier (77) 1 1 0 1 2 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 25 
Messier (78) 1 1 1 1 2 1 1 1 0 1 1 1 0 0 1 1 1 1 0 1 1 1 1 UC 1 1 1 23 
Michel (31) 1 1 1 1 0 0 1 1 0 1 UC UC 1 1 1 1 1 1 1 1 UC 1 1 1 0 0 1 19 
Pavelka (30) 1 1 1 0 1 0 1 1 0 1 UC UC 0 1 1 1 1 1 1 1 0 1 1 UC 1 1 0 18 
Pavelka (81) 1 1 1 1 1 0 1 1 1 1 1 UC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
Rat (82) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 UC 1 1 25 
Raynauld (27) 1 1 1 1 2 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 0 26 
Reginster (83) 1 1 1 1 1 1 1 1 0 1 UC UC 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 22 
Reginster (26) 1 1 1 1 1 0 1 1 0 1 0 UC 1 1 1 1 1 1 1 1 1 1 1 1 UC 1 1 22 
Roman-Blas (24) 1 1 1 1 1 0 1 1 1 1 UC UC 0 1 1 1 1 1 0 1 0 UC 1 1 1 1 0 19 
Rozendaal (31) 1 1 1 1 2 1 1 1 1 0 UC UC 0 1 1 0 1 1 1 1 UC 1 1 1 1 1 UC 21 
Sawitzke (86) 1 0 1 1 2 0 1 1 0 1 1 UC 0 1 1 1 1 1 1 1 UC UC 1 UC 1 UC UC UC 
Spector (89) 1 1 1 1 2 0 1 1 1 1 UC UC 0 UC UC 1 1 1 0 1 0 UC 1 UC 1 1 0 17 
Sun (90) 1 1 1 1 1 1 1 1 1 1 UC UC 1 1 1 1 1 1 1 1 UC 1 1 1 1 1 1 24 
Urish (22) 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 1 0 24 
Weng (91) 1 1 1 1 0 1 1 0 1 0 UC UC 1 0 UC 1 1 1 1 1 UC UC 1 1 0 1 1 17 
Witt (93) 1 1 1 1 1 1 1 1 1 1 UC UC 1 0 0 1 1 1 1 1 UC 1 1 1 1 1 1 22 
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5. Are the distributions of principal confounders in each group of subjects to be compared clearly described?  
6. Are the main findings of the study clearly described?  
7. Does the study provide estimates of the random variability in the data for the main outcomes?  
8. Have all important adverse events that may be a consequence of the intervention been reported?  
9. Have the characteristics of patients lost to follow-up been described? 
10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 
0.001? 
11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?  
12. Were those subjects who were prepared to participate representative of the entire population from which they were recruited? 
13. Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?  
14. Was an attempt made to blind study subjects to the intervention they have received?  
15. Was an attempt made to blind those measuring the main outcomes of the Intervention? 
16. If any of the results of the study were based on “data dredging”, was this made clear?  
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period 
between the intervention and outcome the same for cases and controls? 
18. Were the statistical tests used to assess the main outcomes appropriate? 
19. Was compliance with the intervention/s reliable?  
20. Were the main outcome measures used accurate (valid and reliable)? 
21. Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from 
the same population?  
22. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over 
the same period of time?  
23. Were study subjects randomized to intervention groups?  
24. Was the randomized intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable?  
25. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?  
26. Were losses of patients to follow-up taken into account? 
27. Was there sufficient power to detect treatment effect at significance level of 0.05? 
 
 
 
